Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. KMTS
KMTS logo

KMTS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Kestra Medical Technologies Ltd (KMTS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
19.930
1 Day change
4.45%
52 Week Range
30.000
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Kestra Medical Technologies Ltd (KMTS) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of positive trading signals, neutral technical indicators, absence of recent news or significant catalysts, and no clear financial data make it prudent to hold off on investing in this stock right now.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating a bearish trend. The RSI is neutral at 50.766, showing no clear momentum. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near the pivot point of 19.884, with resistance at 21.008 and support at 18.761.

Positive Catalysts

  • NULL identified. No recent news or significant events to act as a positive catalyst.

Neutral/Negative Catalysts

  • Bearish technical indicators and lack of significant trading trends from hedge funds or insiders. Analysts have lowered the price target from $32 to $30, reflecting cautious sentiment.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

BTIG maintains a Buy rating but has lowered the price target from $32 to $30 due to updates in CMS regulations. Analysts remain cautiously optimistic but have adjusted expectations downward.

Wall Street analysts forecast KMTS stock price to rise
6 Analyst Rating
Wall Street analysts forecast KMTS stock price to rise
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 19.080
sliders
Low
27
Averages
29.5
High
32
Current: 19.080
sliders
Low
27
Averages
29.5
High
32
BTIG
Buy
downgrade
$32 -> $30
AI Analysis
2026-04-13
Reason
BTIG
Price Target
$32 -> $30
AI Analysis
2026-04-13
downgrade
Buy
Reason
BTIG lowered the firm's price target on Kestra Medical to $30 from $32 and keeps a Buy rating on the shares as part of a broader research name on Medical Technology. The firm is updating its models to reflect the CMS having announced its proposed rule for the FY27 inpatient prospective payment system which includes, among other things, preliminary commentary and decisions regarding new technology add-on payments, the analyst tells investors in a research note.
Goldman Sachs
Neutral
downgrade
$27 -> $24
2026-01-16
Reason
Goldman Sachs
Price Target
$27 -> $24
2026-01-16
downgrade
Neutral
Reason
Goldman Sachs lowered the firm's price target on Kestra Medical to $24 from $27 and keeps a Neutral rating on the shares. MedTech and Healthcare IT stocks fell sharply from January 8-14, declining about 3% and 11%, respectively, in a move that appears largely disconnected from fundamentals, the analyst tells investors in a research note. Even companies pre-announcing above-consensus results saw share weakness, despite forward outlooks generally at or above current Street expectations, the firm says.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for KMTS
Unlock Now

People Also Watch